Ubiquitin Proteasome System Dysfunction In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.
The ubiquitin-proteasome system (UPS) is the primary pathway for targeted degradation of misfolded, damaged, or short-lived regulatory proteins. It involves the covalent attachment of ubiquitin molecules to target proteins, followed by recognition and degradation by the proteasome. Dysfunction of the UPS is a common feature in neurodegenerative diseases, where accumulation of ubiquitinated protein aggregates is a hallmark pathological finding.
flowchart TD
A[E1 - Ubiquitin-Activating<br/Enzyme] -->|ATP-dependent| B[E2 - Ubiquitin-Conjugating<br/Enzyme]
B --> C[E3 - Ubiquitin Ligase<br/Substrate recognition]
C --> D[Ubiquitin-Protein<br/Conjugate]
D --> E{Mono vs Poly<br/Ubiquitination}
E -->|K48 linkage| F[Proteasomal<br/Degradation]
E -->|K63 linkage| G[Autophagy<br/Signaling]
E -->|K27, K29, K33| H[Non-degradative<br/Functions]
E -->|Mono Ub| I[Signaling<br/Endocytosis]
- ~10 E1 enzymes in humans
- Activate ubiquitin in an ATP-dependent manner
- Transfer ubiquitin to E2 enzymes
- ~40 E2 enzymes in humans
- Determine chain linkage type
- Work with specific E3 enzymes
-
600 E3 ligases in humans
- Provide substrate specificity
- Two main classes:
- RING finger: Bridge E2 and substrate
- HECT: Form E3-Ub intermediate
| Component |
Function |
Disease Links |
| Ubiquitin |
Small protein modifier |
Ubiquitin inclusions |
| Parkin |
E3 ligase (PD) |
Autosomal recessive PD |
| PINK1 |
Kinase that activates Parkin |
Familial PD |
| VCP/p97 |
Extract ubiquitinated proteins |
ALS, FTD |
| Proteasome (26S) |
Degrade polyubiquitinated proteins |
Impaired in AD |
| USP proteins |
Deubiquitinating enzymes |
Dysregulated in disease |
The 26S proteasome consists of:
-
20S Core Particle (CP): Proteolytic chamber
- Alpha rings (7 subunits): Gate entry
- Beta rings (7 subunits): Catalytic (beta1, beta2, beta5)
-
19S Regulatory Particle (RP)
- Base: ATPases, ubiquitin receptors
- Lid: Deubiquitinating enzymes
- PINK1/Parkin pathway: Impaired mitophagy
- FBXO7: Mutations cause early-onset PD
- Ubiquitated Lewy bodies: Alpha-synuclein inclusions
- UCHL1: Loss of function reduces proteasomal activity
- Proteasome impairment: Reduced activity in affected brain regions
- Tau inclusions: Ubiquitinated
- Ubiquitin carboxy-terminal hydrolase L1 (UCHL1): Reduced in AD
- ERAD dysfunction: Accumulation of misfolded proteins
- UBQLN2: Mutations cause ALS/FTD
- VCP/p97: Mutations cause inclusion body myopathy with FTD
- OPTN: Autophagy receptor with UPS roles
- C9orf72: Affects protein homeostasis
- Mutant huntingtin: Impairs proteasome function
- Ubiquitin-positive inclusions: Characteristic pathology
- TRIP12: E3 ligase affecting mutant HTT clearance
| Target |
Approach |
Examples |
| Proteasome activators |
Enhance activity |
Lactacystin derivatives |
| E3 ligase modulators |
Adjust ubiquitination |
Parkin activators |
| DUB inhibitors |
Prevent deubiquitination |
USP14 inhibitors |
| Aggregate clearance |
Enhance clearance |
ASO, small molecules |
| UPS gene therapy |
Restore function |
AAV-Parkin |
The study of Ubiquitin Proteasome System Dysfunction In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Hershko A, Ciechanover A. The ubiquitin system. Annual Review of Biochemistry (2022)
- Cook C, et al. Ubiquitin-proteasome system in Alzheimer's disease. Journal of Neurochemistry (2023)
- Upadhyay M, et al. Parkin and PINK1 in Parkinson's disease. Nature Reviews Neuroscience (2023)
- Dantuma NP, et al. The ubiquitin-proteasome system in neurodegeneration. Nature Reviews Neurology (2024)
- Klein K, et al. Proteasome dysfunction in neurodegenerative diseases. Nature Reviews Drug Discovery (2023)
- Rothenberg C, et al. Ubiquitin homeostasis in neurodegeneration. Brain (2023)
- Liu H, et al. VCP mutations in ALS/FTD. Molecular Neurodegeneration (2022)
- Wang H, et al. Proteasome activation in neurodegeneration. Trends in Neurosciences (2023)
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
8 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 29%